Browse UBR5

Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF11547 E3 ubiquitin ligase EDD
PF00632 HECT-domain (ubiquitin-transferase)
PF00658 Poly-adenylate binding protein
Function

E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation (By similarity). Involved in maturation and/or transcriptional regulation of mRNA by activating CDK9 by polyubiquitination. May play a role in control of cell cycle progression. May have tumor suppressor function. Regulates DNA topoisomerase II binding protein (TopBP1) in the DNA damage response. Plays an essential role in extraembryonic development. Ubiquitinates acetylated PCK1. Also acts as a regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes.

> Gene Ontology
 
Biological Process GO:0000060 protein import into nucleus, translocation
GO:0000209 protein polyubiquitination
GO:0006282 regulation of DNA repair
GO:0006302 double-strand break repair
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0009755 hormone-mediated signaling pathway
GO:0016055 Wnt signaling pathway
GO:0016570 histone modification
GO:0016574 histone ubiquitination
GO:0017038 protein import
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031056 regulation of histone modification
GO:0031057 negative regulation of histone modification
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0033158 regulation of protein import into nucleus, translocation
GO:0033160 positive regulation of protein import into nucleus, translocation
GO:0033182 regulation of histone ubiquitination
GO:0033183 negative regulation of histone ubiquitination
GO:0033522 histone H2A ubiquitination
GO:0034504 protein localization to nucleus
GO:0035411 catenin import into nucleus
GO:0035412 regulation of catenin import into nucleus
GO:0035413 positive regulation of catenin import into nucleus
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043401 steroid hormone mediated signaling pathway
GO:0044744 protein targeting to nucleus
GO:0045738 negative regulation of DNA repair
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048545 response to steroid hormone
GO:0050847 progesterone receptor signaling pathway
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0060070 canonical Wnt signaling pathway
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0070534 protein K63-linked ubiquitination
GO:0070535 histone H2A K63-linked ubiquitination
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090316 positive regulation of intracellular protein transport
GO:0198738 cell-cell signaling by wnt
GO:1900044 regulation of protein K63-linked ubiquitination
GO:1900045 negative regulation of protein K63-linked ubiquitination
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901314 regulation of histone H2A K63-linked ubiquitination
GO:1901315 negative regulation of histone H2A K63-linked ubiquitination
GO:1902275 regulation of chromatin organization
GO:1902593 single-organism nuclear import
GO:1902914 regulation of protein polyubiquitination
GO:1902915 negative regulation of protein polyubiquitination
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
GO:1905268 negative regulation of chromatin organization
GO:2000779 regulation of double-strand break repair
GO:2000780 negative regulation of double-strand break repair
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0032182 ubiquitin-like protein binding
GO:0034450 ubiquitin-ubiquitin ligase activity
GO:0043130 ubiquitin binding
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
Reactome -
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBR5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBR5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: 1.15; FDR: 0.046600 Sensitive to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1910.492
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2820.859
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1240.917
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0460.882
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.070.981
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0120.998
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0730.874
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1050.96
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0350.988
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0440.975
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9550.631
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0630.332
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.54.114.40.0315
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.53.415.10.0291
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBR5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBR5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBR5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBR5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBR5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBR5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBR5
Nameubiquitin protein ligase E3 component n-recognin 5
Aliases DD5; HYD; EDD; KIAA0896; EDD1; E3 ubiquitin protein ligase, HECT domain containing, 1; E3 identified by diff ......
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBR5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.